Biologics Outsourcing Market

Short answer for a buyer asking how big biologics outsourcing is: USD 28.63 billion of revenue in 2025, heading for USD 70.4 billion in 2035 at a 9.41% revenue CAGR. The biologics outsourcing market covers contract development, manufacturing and testing of antibody, protein and vaccine medicines that contract development and manufacturing organisations (CDMOs) carry out for drug sponsors. Our 2025 figure is 6.618 million revenue-bearing litre-equivalents of contracted bioreactor capacity multiplied by USD 4,326 per litre-equivalent per year, which equals USD 28.63 billion. Sourcing rules shifted on 18 December 2025, when the National Defense Authorization Act for Fiscal Year 2026 became Public Law 119-60, carrying the BIOSECURE Act limits on federal contracts that rely on biotechnology companies of concern. The study belongs to our pharmaceutical manufacturing services research, and every number follows the Douglas Insights research methodology.

How much do sponsors pay per litre of contracted bioreactor time?

Douglas Insights puts the blended realised biologics outsourcing price at USD 4,326 per litre-equivalent per year in 2025, rising to USD 5,232 by 2035 on a 1.92% annual price leg. Clinical batches and antibody-drug conjugates command premiums, while large commercial monoclonal antibody campaigns set the floor of the price band.

Our realised bands run from about USD 2,900 to USD 4,100 per litre-year for commercial Mammalian cell culture on 15,000 to 20,000-litre stainless trains, USD 6,800 to USD 9,500 for clinical drug substance work on 2,000-litre single-use bioreactors, and above USD 12,000 for conjugation suites with high-potency containment. Microbial fermentation for recombinant proteins prices lower, near USD 2,400 per litre-year, because cycle times are shorter. Short contracts pay more. A sponsor signing a 7-year take-or-pay commercial reservation secures 15% to 22% below the spot rate for a single campaign, by Douglas Insights estimate.

A cross-check comes from the largest single site owner. Samsung Biologics reported 2025 revenue of 4,557.0 billion Korean won (KRW), up 30.3%, with operating profit of KRW 2,069.2 billion. Spread over the 604 thousand litres (kL) that earned revenue before Plant 5 contributes in 2026, the biologics outsourcing yield is KRW 7.54 million per litre, about USD 5,313 at our assumed conversion of KRW 1,420 per US dollar. Samsung therefore earns 22.8% more per litre than our blended price, a gap Douglas Insights attributes to high utilisation of large antibody reactors. Samsung guides to 15% to 20% revenue growth for 2026.

Build cost anchors the price floor. FUJIFILM Biotechnologies invested USD 3.2 billion in its Holly Springs, North Carolina site, whose first phase holds 8 bioreactors of 20,000 litres, with 16 at full build. Douglas Insights arithmetic gives USD 20,000 of investment per litre of phase-one volume, so the operator needs about 4.6 years of blended biologics outsourcing revenue per litre to recover the outlay.

Which molecules and services fall inside biologics outsourcing?

Biologics outsourcing comprises five service lines that sponsors buy from CDMOs across five molecule groups, and Monoclonal antibodies take 58.3% of 2025 revenue in our model. Commercial antibody campaigns still fill most contracted litres, so antibody demand sets the pace for the whole biologics outsourcing total through 2035.

By molecule, Antibody-drug conjugates hold 9.8%, Bispecific antibodies 7.6%, Recombinant proteins 15.1% and Vaccines 9.2% of biologics outsourcing revenue. By expression system, Mammalian cell culture earns 81.3% and Microbial fermentation 18.7%. By customer, Large pharma buys 54.6% of contracted litres and Small and mid-size biotech 45.4%, a share that rises when venture funding recovers. Cell and gene therapies sit outside this scope and appear in our Cell and Gene Therapy CDMO Services Market study. Bags, filters and other consumables bought by the CDMOs belong to the Biopharmaceutical Single-Use Bioprocessing Market, so equipment spend is not counted twice.

Which service segment makes the money in biologics outsourcing?

Commercial drug substance manufacturing leads biologics outsourcing with 38.6% of revenue, USD 11.1 billion in 2025, because approved antibodies run multi-year supply contracts on large bioreactors. Drug product fill-finish grows fastest at 10.48% a year as sponsors move prefilled syringe and vial work to CDMOs.

Commercial drug substance manufacturing is worth USD 11.1 billion and reaches USD 25.5 billion by 2035; its share holds because a single blockbuster antibody can occupy a 15,000-litre train for most of a year. Clinical drug substance manufacturing earns USD 4.95 billion and grows 9.62% a year, fed by phase 1 to phase 3 programmes from biotech sponsors without their own plants. Drug product fill-finish contributes USD 4.84 billion today and USD 13.1 billion by 2035; aseptic filling of high-concentration antibodies in syringes and autoinjectors is the fastest-growing line at 10.48%, and the adjacent Sterile Injectable Contract Manufacturing Market study tracks the wider fill capacity. Process and cell line development delivers USD 4.04 billion at 9.95% a year, the entry ticket that locks a molecule to one CDMO before clinical supply. Analytical and testing services add USD 3.75 billion, growing 9.27% as release testing, stability studies and comparability work for biosimilars scale with batch counts.

Why are biologic sponsors handing more bioreactor work to CDMOs?

Contracted biologics outsourcing volume grows 7.35% a year because four forces add litres: new biologic approvals, US onshoring of antibody supply, harder molecule formats and biosimilar launches. Douglas Insights counts 2.64 points from pipeline approvals alone, the largest single source of new contracted litres through 2035.

Approvals first. The US Food and Drug Administration (FDA) Center for Drug Evaluation and Research approved 46 novel drugs in 2025, and its list includes antibody approvals such as Andembry (garadacimab), Enflonsia (clesrovimab) and Imaavy (nipocalimab). Our model assumes each commercial antibody launch books 2 to 6 manufacturing campaigns a year at a CDMO before a sponsor decides whether to build its own plant. Douglas Insights attributes 2.64 points of the 7.35% volume leg to this pipeline flow, worth about 175,000 extra contracted litre-equivalents in 2026 alone.

US onshoring adds 1.83 points. The BIOSECURE provisions signed on 18 December 2025 give federal contractors a reason to move antibody programmes to US, European and Korean plants before the Office of Management and Budget (OMB) list of biotechnology companies of concern, due in December 2026. Lonza’s Vacaville, California site generated around 0.6 billion Swiss francs (CHF) of sales in 2025 and signed a fifth significant commercial contract, according to Lonza’s full-year 2025 results, which also show +32.2% constant exchange rate (CER) sales growth for the Integrated Biologics platform. Samsung Biologics is buying a Rockville, Maryland facility with 60 kL of drug substance capacity. Douglas Insights expects North American contracted litres to rise 9.17% a year in revenue terms on this shift.

Harder formats add 1.57 points. Antibody-drug conjugates and Bispecific antibodies need conjugation suites, potent-compound containment and more analytical release tests per batch, which few sponsors want to own. Lonza’s Integrated Biologics growth of 32.2% at CER is the clearest sign that complex biologics are being sent out. Our model gives these two formats 17.4% of biologics outsourcing revenue in 2025 and roughly 23% by 2035.

Biosimilar programmes add the last 1.31 points. As patents on large antibodies expire through 2035, biosimilar developers, most of them without large stainless capacity, buy process development, clinical comparability batches and then commercial runs from CDMOs. Douglas Insights values biosimilar-related work at about 11.6% of 2025 contracted litres, rising to about 14% by 2035. Together the four drivers add 2.64 + 1.83 + 1.57 + 1.31 = 7.35 points, which is the full volume leg of the forecast.

What limits CDMO bioreactor utilisation and slows biologics outsourcing?

Three brakes remove 1.93 points from biologics outsourcing volume growth: idle bioreactor capacity, sponsors pulling plants back in-house and the cost of moving antibody programmes away from Chinese CDMOs. Without them the volume leg would run at 9.28% a year instead of 7.35%, a gap worth billions of dollars by 2035.

Overbuilt capacity takes 0.84 points. Samsung Biologics alone runs 784 kL after Plant 5 and FUJIFILM is adding 16 bioreactors of 20,000 litres in North Carolina, so contract capacity grows faster than committed demand in 2026 and 2027. Douglas Insights estimates blended utilisation of large-scale contract antibody trains at about 71% in 2025, and every 5 points of idle capacity pushes CDMOs to discount commercial reservations rather than add revenue-bearing litres.

Sponsors buying plants take 0.62 points. Novo Holdings completed its acquisition of Catalent on 18 December 2024 at an enterprise value of about USD 16.5 billion, and three fill-finish sites in Anagni, Bloomington and Brussels passed to Novo Nordisk. Each such deal turns contract litres into captive litres and removes them from the biologics outsourcing count. Switching costs take the final 0.47 points: a commercial antibody transfer needs new process performance qualification (PPQ) batches and regulatory filings, which our model sets at 18 to 30 months of work, so sponsors leaving Chinese suppliers delay volume rather than move it at once.

Which companies win the largest monoclonal antibody manufacturing contracts?

Douglas Insights estimates that Lonza, Samsung Biologics and WuXi Biologics together hold 35.4% of biologics outsourcing revenue in 2025, anchored on their disclosed sales converted at assumed average exchange rates. Lonza leads at about 13.6%, followed by Samsung Biologics at 11.2% and WuXi Biologics at 10.6%.

Lonza’s lead rests on breadth: its Integrated Biologics platform grew 32.2% at CER, and Vacaville adds a large US commercial site. Samsung Biologics wins on scale and speed, with Plant 5 adding 180,000 litres at Bio Campus II and a 2026 revenue guide of 15% to 20% growth. WuXi Biologics reported revenue of RMB 21.8 billion, up 16.7%, with a backlog of USD 23.7 billion and 209 new integrated projects, though the BIOSECURE law weighs on its US-funded work. FUJIFILM Biotechnologies competes on large 20,000-litre plant designs, led by Holly Springs in North Carolina. Thermo Fisher Scientific has added Sanofi’s Ridgefield, New Jersey sterile fill-finish site to its network. Catalent, now owned by Novo Holdings, competes with a smaller network after three fill-finish sites moved to Novo Nordisk. Douglas Insights puts the next seven CDMOs at a further 21.8% of revenue, leaving a long tail of regional and specialist firms with 42.8%.

Where is new biologics CDMO capacity rising, region by region?

North America leads biologics outsourcing with USD 11.9 billion in 2025, 41.7% of revenue, while Asia Pacific grows fastest at 11.63% a year on Korean antibody plants such as Samsung Biologics’ 180,000-litre Plant 5. Europe holds USD 8.42 billion, and the two smallest regions together hold USD 1.46 billion.

North America reaches USD 28.7 billion by 2035 at 9.17% a year, helped by FUJIFILM in North Carolina, Lonza in Vacaville and BIOSECURE-driven transfers. Europe grows 7.86% a year to USD 17.9 billion, the slowest rate, because Douglas Insights sees new European contract builds lagging US ones through 2030. Asia Pacific climbs from USD 6.81 billion to USD 20.5 billion; Korea gains share while China’s growth depends on non-US customers. Latin America earns USD 830.3 million in 2025 and USD 1.87 billion by 2035 at 8.47%, mostly biosimilar development and testing work in our model. The wildcard is the Middle East and Africa, at USD 629.8 million growing 8.21% a year to USD 1.39 billion, a rate our model would lift by about 2 points if a single large antibody fill-finish plant opened in the Gulf.

Are antibody-drug conjugates and bispecific antibodies rewriting biologics outsourcing contract terms?

Yes: antibody-drug conjugates and bispecific antibodies carry 17.4% of biologics outsourcing revenue in 2025 in our model, and their contracts run longer and pay more per litre. Conjugation needs potent-payload containment and dual supply chains, so sponsors sign integrated deals covering antibody, linker, payload and fill.

Douglas Insights estimates a conjugate programme earns 2.8 times the revenue per litre of a plain antibody campaign, because conjugation, purification and release testing add steps after the bioreactor. Bispecific antibodies earn about 1.4 times, mainly from extra purification and analytics to remove mispaired chains. Contract terms change with the molecule: integrated antibody-drug conjugate deals typically bundle 3 to 4 service lines, and Douglas Insights counts at least 2 of every 5 new conjugate programmes signing with a single CDMO for the whole chain.

Which rules govern biologics outsourcing under BIOSECURE and current good manufacturing practice?

Two rule sets shape biologics outsourcing contracts: current good manufacturing practice (cGMP) inspections for every licensed biologic site, and the BIOSECURE law, whose OMB list of biotechnology companies of concern is due in December 2026. Existing contracts receive a 5-year wind-down, so the volume shift is gradual.

Under BIOSECURE, OMB guidance follows in June 2027 and Federal Acquisition Regulation changes take effect around June 2028, 60 days after for entities already on the Department of Defense 1260H list and 90 days for others. Companies already on the 1260H list on the signing date do not get the grandfather period. On the quality side, each new commercial antibody needs a pre-license inspection (PLI) of the CDMO plant by the FDA, and a site transfer needs fresh PPQ batches. Douglas Insights counts these 2 regulatory gates as the main reason commercial biologics outsourcing contracts last 5 to 10 years.

What if BIOSECURE enforcement or biologic approvals shift the 2035 biologics outsourcing figure?

Our biologics outsourcing base case gives USD 70.4 billion in 2035 from 7.35% volume and 1.92% price growth; a slower case gives USD 53.0 billion and a faster case USD 92.6 billion. The swing factors are the pace of biologic approvals, how fast BIOSECURE moves work out of China, and whether CDMOs fill new 20,000-litre trains.

The slower case uses 5.10% volume and 1.20% price growth, a 6.36% revenue CAGR: approvals slip below 40 a year, sponsors keep buying plants as Novo Nordisk did with the Catalent sites, and idle capacity forces deeper discounts. The faster case uses 9.60% volume and 2.60% price growth, a 12.45% revenue CAGR: BIOSECURE transfers land early after the December 2026 OMB list and conjugate demand doubles its share. A single extra point of annual volume growth adds about USD 6.84 billion to the 2035 base value. Outside forecasts we reviewed span 7.14% to 16.0% a year, and our 9.41% lands in the lower third of that spread because our model nets out idle capacity and sponsor-owned plants.

Douglas Exclusive: the Biologics CDMO Capacity Atlas

The Biologics CDMO Capacity Atlas is a Douglas Insights model, not an official register, built from 31 inputs: 11 company disclosures read for this edition and 20 modelled regional and service-line parameters. The atlas maps named contract bioreactor capacity to country and region, then compares where new litres land with where revenue sits today.

Its headline finding: of the 560 kL of new or acquired contract capacity named in the three largest disclosures we read, 380 kL, or 67.9%, sits in the United States. Those disclosures are FUJIFILM’s Holly Springs site at 320 kL when all 16 bioreactors of 20,000 litres are installed, Samsung Biologics’ 60 kL Rockville, Maryland purchase and Samsung’s 180 kL Plant 5 in Songdo. North America holds 41.7% of biologics outsourcing revenue today, so new US capacity runs well ahead of the region’s revenue weight. The atlas therefore flags 2027 to 2029 as a period of US price pressure on commercial reservations, and Douglas Insights expects US realised prices per litre to trail the global 1.92% price leg by about 0.4 points in those years.

Which methodology turns contracted litre-equivalents into the biologics outsourcing figure?

The model multiplies 6.618 million revenue-bearing litre-equivalents by USD 4,326 per litre-year to reach USD 28.63 billion in 2025, then grows volume 7.35% and price 1.92% a year to USD 70.4 billion by 2035. Five regional blocks and five service segments reconcile to the global total.

Volume in 2035 reaches 13.45 million litre-equivalents and price reaches USD 5,232. The data set holds 14 checked source facts, 7 published outside growth rates and 31 atlas inputs. Cross-check one: outside base-year estimates for the narrower contract manufacturing scope run from USD 23.1 billion to USD 25.9 billion, and our figure sits 10.4% above the top of that range because it adds development and testing revenue. Cross-check two: Samsung Biologics earns about USD 5,313 per revenue-bearing litre, 22.8% above our blended price, consistent with its high-utilisation antibody mix. Cross-check three: the regional rows sum to USD 28.63 billion in 2025 and USD 70.4 billion in 2035 to within USD 0.1 million, and the five segment values for 2035 sum to within 0.3% of the global figure.

Sources

1. US Government Publishing Office Public Law 119-60, National Defense Authorization Act for Fiscal Year 2026 (2025)
2. Lonza Lonza full-year 2025 results (2026)
3. Samsung Biologics Samsung Biologics fourth quarter and fiscal year 2025 results (2026)
4. FUJIFILM FUJIFILM Biotechnologies Holly Springs grand opening (2025)
5. Novo Holdings Novo Holdings completes acquisition of Catalent (2024)
6. US Food and Drug Administration Novel Drug Approvals for 2025 (2025)
7. SEC EDGAR Thermo Fisher Scientific fourth quarter and full year 2025 results (Form 8-K exhibit) (2026)
8. Samsung Biologics Samsung Biologics Plant 5 capacity announcement (2023)